Reithera Srl, The Ragon Institute of Mass General, MIT and Harvard, and IAVI have established a collaboration to develop a novel HIV vaccine candidate based on gorilla adenoviral vector (GRAd), with funding by the Bill & Melinda Gates Foundation.

Proteinlogic Ltd. and Stellenbosch University have received a $1.35 million grant from the Bill & Melinda Gates Foundation to develop a blood test to monitor treatment responses to tuberculosis (TB) antimicrobial chemotherapy.

The COVID-19 virus may keep mutating, but new findings from Korean researchers at the Institute of Basic Science (IBS) offer a silver lining: human immunity is adapting, too.

Researchers from National Institute of Allergy and Infectious Diseases and affiliated organizations presented data from a study that aimed to assess the protective efficacy of the human fusion peptide (FP) broadly neutralizing antibody (bNAb), VRC34.01, along with two FP vaccine-elicited rhesus macaque mAbs, DFPH-a.15 and DF1W-a.01, to protect naïve rhesus macaques against mucosal challenge with SHIV(BG505).

Researchers at ETH Zurich have identified a proteomic signature that could recognize long COVID six months after acute infection. Biologically, the signature indicated that the complement system remained active in patients with long COVID six months after infection. Translationally, it could lead to a diagnostic test for long COVID, and suggests that targeting the complement system could be a therapeutic approach to prevent or treat the disorder.

Malaria cases increase at a slow but continued rate. There is a vital need for new antimalarial treatments able to overcome drug resistance for a more sustained control of the disease.

Basilea Pharmaceutica Ltd. has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting gram-negative bacteria, including multidrug-resistant strains.